GENFIT is a biopharmaceutical company that focuses on developing diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. Its lead pipeline product elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis). Genfit SA was founded in 1999 and is headquartered in Loos, France.
There are currently no products available for this company. Please contact us for more information or browse other companies.